Clinical Trial

A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment

Study acronym: MRD
Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated July 5, 2024 (before its estimated January 10, 2025 completion). Its status may not reflect the trial's current state.
Summary
The aim of this study was to observe the rate of MRD conversion and the impact on survival in newly diagnosed multiple myeloma (NDMM) patients with persistent MRD positivity after induction and consolidation therapy (autologous hematopoietic stem cell transplantation or consolidation of the original regimen) who were switched to high-intensity therapy, and to compare the rate of persistent MRD-negativity, progression-free survival (PFS), and overall survival (OS) between the two groups in comparison with NDMM patients who achieved MRD-negativity after the same induction and consolidation therapy.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06109233
Lead Sponsor FengYan Jin
Conditions Multiple Myeloma, Minimal Residual Disease
Enrollment 80 participants
Start Date 2022-01-10
Primary Completion 2025-01-10 (estimated)
Study Completion 2026-01-10 (estimated)
Updated on ClinicalTrials.gov 2024-07-05